Atea Pharmaceuticals Inc (AVIR)

Mar 10, 2025

What is William Blair’s Forecast for AVIR Q1 Earnings? - Defense World

Mar 10, 2025

Mar 09, 2025

William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - Defense World

Mar 09, 2025

Mar 09, 2025

Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts - MSN

Mar 09, 2025

Mar 08, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 08, 2025

BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat

Mar 08, 2025

Mar 07, 2025

Atea Pharmaceuticals’ Promising Earnings Call Highlights - TipRanks

Mar 07, 2025

Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025

Mar 07, 2025

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Benzinga

Mar 07, 2025

Mar 06, 2025

Atea Pharmaceuticals Advances HCV Program with FDA Approval - TipRanks

Mar 06, 2025

Mar 06, 2025

Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock - Investing.com

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Cuts Workforce by 25% - MarketWatch

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c) - TipRanks

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian

Mar 06, 2025

Mar 06, 2025

Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 - StockTitan

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Inc. (AVIR) reports earnings - Quartz

Mar 06, 2025

Mar 01, 2025

Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 01, 2025

Feb 27, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Feb 27, 2025

Feb 27, 2025

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Atea Pharmaceuticals to Host Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq

Feb 27, 2025

Feb 27, 2025

When Will Atea Pharmaceuticals Reveal Its Antiviral Pipeline Progress? Key Date for Biotech Investors - StockTitan

Feb 27, 2025

Feb 27, 2025

Atea Pharmaceuticals Appoints Arthur Kirsch as Class I Director Amid Voting Agreement Disclosure - Defense World

Feb 27, 2025

Feb 25, 2025

Atea Pharmaceuticals appoints Arthur Kirsch to Board By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 24, 2025

Atea Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals Appoints Arthur Kirsch as Director - TipRanks

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals appoints new board member - Investing.com India

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals appoints Arthur Kirsch to Board - Investing.com India

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors - GlobeNewswire

Feb 24, 2025

Feb 24, 2025

Can This Healthcare Finance Expert Help Accelerate Atea's HCV Drug Development? - StockTitan

Feb 24, 2025

Feb 22, 2025

Atea Pharmaceuticals (AVIR) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Feb 22, 2025

Feb 18, 2025

Collegium Pharmaceutical (NASDAQ:COLL) versus Atea Pharmaceuticals (NASDAQ:AVIR) Critical Survey - Defense World

Feb 18, 2025

Feb 17, 2025

Peapod Lane Capital LLC Acquires New Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat

Feb 17, 2025

Feb 17, 2025

Stocks of Atea Pharmaceuticals Inc (AVIR) are poised to climb above their peers - SETE News

Feb 17, 2025

Feb 10, 2025

Roche Walks Away From Atea Partnership To Develop COVID Pill - BW Healthcare World

Feb 10, 2025

Feb 06, 2025

February 2025 US Penny Stocks To Watch - Simply Wall St

Feb 06, 2025

Feb 06, 2025

Director BERGER FRANKLIN M sale 359,606 shares of Atea Pharmaceuticals Inc [AVIR] - Knox Daily

Feb 06, 2025

Feb 04, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - MarketBeat

Feb 04, 2025

Jan 31, 2025

JPMorgan Chase & Co. Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jan 31, 2025

Jan 19, 2025

Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN

Jan 19, 2025

Jan 18, 2025

Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9% - MarketBeat

Jan 18, 2025

Jan 17, 2025

Franklin Berger Increases Stake in Atea Pharmaceuticals Inc (AVI - GuruFocus.com

Jan 17, 2025

Jan 17, 2025

Barclays PLC Buys 75,624 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat

Jan 17, 2025

Jan 17, 2025

Barclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jan 17, 2025

Jan 13, 2025

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 13, 2025